20
Erregierre Spa, based in Italy, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is RIVASTIGMINE, with a corresponding US DMF Number 25871.
Remarkably, this DMF maintains an Active status since its submission on December 22, 2011, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of October 29, 2014, and payment made on September 24, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II